Management Communication_Task 1: Executive Summary
Western Governor’s University
In the United States alone, 2.8 million breast cancer survivors currently reside. Studies indicate
that breast cancer recurs in 11% of patients within five years, and 20% of patients within ten
years (as quoted by Dawson, G. via American Cancer Society, 2008). Sienna Pharmaceuticals
mission since being founded has been to save lives. Therefore, it is with great excitement that I
introduce you to an extremely promising product that has garnered much anticipation within the
market as to the potential of its efficacy. Complexia has been formulated to prevent recurrence of
breast cancer during and after chemotherapy has been completed. A woman’s risk of breast
cancer recurrence depends on many factors such as age at diagnosis, stage of cancer at diagnosis,
and the grade of breast cancer (as quoted by Dawson, G. via American Cancer Society, 2008).
Initial clinical trials have yielded extremely promising results in preventing recurrence of breast
cancer with Complexia in a diverse group of patients.
Araba, the company that developed and will manufacture Complexia does not have distribution
capability and has awarded Sienna Pharmaceuticals exclusive distribution rights. Shipping Inc.
manufactures the refrigerated casing designed specifically for this product, and...